![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 92.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:8068B Amarin Corporation Plc 09 August 2007 AMARIN CORPORATION PLC LONDON, United Kingdom, August 9, 2007 Amarin Corporation plc ("Amarin" or "Company") announces, in accordance with the UK Financial Services Authority's Disclosure and Transparency Rules (the "Disclosure and Transparency Rules"), that the Company's issued share capital as of today's date consists of 97,766,470 ordinary shares with voting rights, which represents the total number of voting rights in the Company. 200,797 of these shares are held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or a change to an interest in, the share capital of the Company under the Disclosure and Transparency Rules. About Amarin Amarin is committed to improving the lives of patients suffering from diseases of the central nervous system. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's core development pipeline includes, in addition to Miraxion for several therapeutic indications, four other key development programs in Parkinson's disease, epilepsy seizures, memory and cognition and our proprietary pre-clinical combinatorial lipid program. Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. For press releases and other corporate information, visit the Amarin website at www.amarincorp.com. Information on our website does not form part of this press release. Contacts: Amarin +44 (0) 207 907 2442 Rick Stewart Chief Executive Officer Alan Cooke President & Chief Financial Officer investor.relations@amarincorp.com Investors: Lippert/Heilshorn & Associates, Inc. +1 212 838 3777 Kim Golodetz Anne Marie Fields Media: Powerscourt +44 (0) 207 250 1446 Rory Godson Victoria Brough Broker: Davy Ivan Murphy +353 (0) 1 679 6363 Fergal Meegan Ends. This announcement has been issued through the Companies Announcement Service of The Irish Stock Exchange This information is provided by RNS The company news service from the London Stock Exchange END ISEDGGGRGLLGNZM
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions